AbbVie has recently announced the latest results from the phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily through 48 weeks.
The results, unveiled at the 2019 European League against Rheumatism (EULAR 2019) from June 12-15 in Madrid, showed the treatment continued to demonstrate improved signs and symptoms of rheumatoid arthritis, as measured by American College of Rheumatology (ACR) 20 and 50, and clinical remission based on Disease Activity Score 28 C-Reactive Protein (DAS28-CRP)<2.6.
The studies evaluate upadacitinib, an investigational, once-daily JAK1-selective inhibitor, in patients with moderately to severely active rheumatoid arthritis.
Besides, data from an integrated safety analysis across five phase 3 SELECT clinical trials showed that treatment with upadacitinib in patients with moderately to severely active rheumatoid arthritis demonstrates a consistent safety profile, the company said in a news release.
"These data continue to support the potential of upadacitinib to help maintain consistent disease control for patients living with moderately to severely active rheumatoid arthritis," said Ronald van Vollenhoven, a professor at Amsterdam Rheumatology and Immunology Center.
While remission is the primary treatment goal, following the American College of Rheumatology and the European League Against Rheumatism recommendations, a majority of patients do not achieve clinical remission today, despite currently available treatment options, he added.
Rheumatoid arthritis is a chronic and debilitating disease that affects an estimated 23.7 million people worldwide. Many patients with rheumatoid arthritis still do not achieve clinical remission or low disease activity targets.
Upadacitinib is an investigational oral agent and has not been approved by any regulatory authorities, AbbVie added.
<© Korea Biomedical Review, All rights reserved.>